SCHEDULE 13G/A: Janus Henderson Group PLC Discloses 5.6% Passive Stake in Edgewise Therapeutics

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Edgewise Therapeutics, Inc. as of March 31, 2025.

Summary

• Janus Henderson Group PLC, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Edgewise Therapeutics, Inc.
• As of March 31, 2025, Janus Henderson Group PLC beneficially owns an aggregate of 5,282,154 shares of Edgewise Therapeutics, Inc. Common Stock.
• This aggregate ownership represents 5.6% of the class of securities.
• The filing indicates shared voting and dispositive power over all 5,282,154 shares.
• The beneficial ownership includes 5,230,450 shares attributed to JHIUS, an indirect subsidiary of Janus Henderson Group PLC.
• The shares are reported as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Indirect subsidiaries, JHIUS, JHIUKL, and JHIAIFML, are identified as registered investment advisers furnishing investment advice to Managed Portfolios, through which these shares are held.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of a passive stake by a large institutional investor. The continued holding of a significant stake (5.6%) by Janus Henderson Group PLC can be seen as a positive signal of confidence, but the document itself contains no new operational or financial news about Edgewise Therapeutics.

Positives

• A significant institutional investor, Janus Henderson Group PLC, maintains a substantial passive stake (5.6%) in Edgewise Therapeutics, indicating continued confidence or interest in the company.
• The filing confirms the investment is for ordinary course of business, not for control, which suggests a stable, long-term investment perspective from a major asset manager.

Future Outlook

No forward-looking statements or guidance from Edgewise Therapeutics are provided in this filing, as this document is a disclosure of ownership by an external entity.

Industry Context

This filing indicates continued institutional interest in Edgewise Therapeutics, a company in the therapeutics sector. Such disclosures are common for publicly traded companies as large asset managers adjust their portfolios, reflecting ongoing market activity and investor positioning.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Janus Henderson Group PLC may be viewed positively, potentially signaling confidence in Edgewise Therapeutics.

Key Dates

Keywords

Edgewise Therapeutics, Janus Henderson Group, Schedule 13G, SEC filing, beneficial ownership, common stock, institutional investment, passive stake, therapeutics